Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Merck's Buyout Of Seagen Hits Speed Braker Over Price Agreement: Report
Via Benzinga
Why Micro Focus International Is Trading Higher By Around 94%; Here Are 28 Stocks Moving Premarket
Gainers 
Via Benzinga
Roche's Polivy Combo Regime Under FDA Review For Type Of Blood Cancer
Via Benzinga
3 Top Stocks to Invest In Right Now
Every investor is looking for the top stocks to invest in. These three options will provide you with both offense and defense. 
Via InvestorPlace
Seagen Q2 Earnings - Better Than Expected, Mum On M&A, Lifts Outlook
Via Benzinga
Seagen Crushes Quarterly Forecasts With Narrower-Than-Expected Losses
Merck is reportedly considering a Seagen buyout. But there are a few boxes to tick. 
Via Investor's Business Daily
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
Via Benzinga
Seagen For Sale? This Acquisition Target Is 'Too Intriguing To Ignore,' RBC Says
The recent pressure on Seagen Inc.’s (NASDAQ: SGEN) stock may offer a nearer-term opportunity, but the biotech's position as an attractive strategic target is “too intriguing to ignore.” 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
  
Via Benzinga
U.S. Stock Futures Edge Lower Ahead Of Walmart, Home Depot Earnings
Pre-open movers 
Via Benzinga
Expert Ratings for Seagen
  Over the past 3 months, 10 analysts have published their opinion on Seagen (NASDAQ:SGEN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
This Analyst Boosts Price Target On Dillard's; Also Check Out Some Other Big PT Changes
JP Morgan raised the price target for Dillard's, Inc. (NYSE: DDS) from $210 to $298. Dillard's shares rose 0.9% to $304.42 in pre-market trading. 
Via Benzinga
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
Via Benzinga
Does Merck Finally Have The Fodder It Needs To Buy Seagen?
The final piece ahead of a potential Seagen buyout took place Friday and shares rose. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Seagen Statement on Outcome of Daiichi Sankyo Arbitration
From Seagen Inc.
Via Business Wire
Seattle Genetics's Return On Capital Employed Overview
According to Benzinga Pro data, during Q2, Seattle Genetics (NASDAQ:SGEN) posted sales of $497.50 million. Earnings were up 1.22%, but Seattle Genetics still reported an overall loss of $134.83... 
Via Benzinga
Recap: Seagen Q2 Earnings
Seagen (NASDAQ:SGEN) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Seagen beat estimated earnings by... 
Via Benzinga
Seagen Reports Second Quarter 2022 Financial Results
From Seagen Inc.
Via Business Wire
7 Stocks to Buy on the Dip
There are many stocks to buy on the dip that look to have lost as much as they will and rebound sometime soon. 
Via InvestorPlace
The 3 Best Market Sectors for the Second Half of 2022
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into. 
Via InvestorPlace
Earnings Scheduled For July 28, 2022
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings for its second quarter. 
Via Benzinga
Analyst Ratings for Seagen
Over the past 3 months, 9 analysts have published their opinion on Seagen (NASDAQ:SGEN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?
One analyst says the study is a "checks-the-box" event for Seagen's potential buyout. 
Via Investor's Business Daily
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Alibaba, General Electric And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Redbox Entertainment Inc. (NASDAQ: RDBX) rose 11.5% to $6.19 in pre-market trading after jumping 82% on Monday. 
Via Benzinga
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial
Via Benzinga
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Why Qudian Shares Jumped Over 40%; Here Are 73 Biggest Movers From Yesterday
Gainers AMTD Digital Inc. (NYSE: HKD) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.